Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

SRI Snags NIH Contract for HIV, AIDS Therapies

By Drug Discovery Trends Editor | July 25, 2014

(Source: SRI International)SRI International has been awarded a new $49 million, seven-year contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to conduct preclinical development of potential therapies for HIV infection and AIDS. The contract supports the development of drugs for treatment of HIV and AIDS and the complications and opportunistic infections associated with the disease, as well as microbicides for preventing sexual transmission of HIV.
 
According to the World Health Organization, more than 35 million people are infected with HIV worldwide. Despite major advances in therapeutics to treat HIV and AIDS, more effective and less toxic drugs and preventive interventions, such as microbicides, to prevent the sexual and perinatal transmission of HIV are still needed.
 
Through the new contract, SRI Biosciences scientists will provide integrated preclinical services to assess the pharmacology and toxicology of potential therapeutic agents and microbicides, and to develop, manufacture and analyze preclinical and clinical dosage formulations. These services will help investigators, small companies and NIH staff obtain the data and products needed to acquire additional funding, gain prospective partnerships, fulfill regulatory requirements and complete studies before entering clinical trials.
 
The contract renews three existing contracts held by SRI, now rolled into a single contract. One of the contracts, initiated 23 years ago, has supported safety testing of more than 200 drugs and therapeutic vaccines at various stages of development. An additional contract first won by SRI in 2000 supports formulation development and clinical manufacturing of drugs for treatment of HIV. A third pharmaceutical resource contract to conduct analytical chemistry evaluation studies was awarded to SRI in 2007.
 
“SRI Biosciences has been supporting NIAID since 1991 in the development of new therapeutics for HIV/AIDS,” said Jon Mirsalis, managing director of SRI Biosciences and co-Principal Investigator for the program. “We are honored to receive this award to continue this vitally important work.” 
 
“We look forward to making additional contributions to translating drug discoveries to the clinic,” said Helen Parish, executive director of the Pharmaceutical Development Section in SRI Biosciences, who is also co-Principal Investigator.
 
Date: July 24, 2014
Source: SRI International

Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE